Wesigamp

Vesigamp is the trade name of a drug whose main active ingredient is Solifenacin. Solifenacin belongs to the class of antimuscarinic drugs that is used to treat symptoms of urinary frequency, urgency incontinence, and urinary incontinence.

The drug "Vesigamp" is intended to reduce the tone of the smooth muscles of the bladder, which leads to a decrease in the urgency of urination and a decrease in the frequency of urination. It blocks muscarinic cholinergic nerve receptors, which in turn leads to decreased bladder activity and improved urinary control.

Symptoms for which Vesigamp may be prescribed include frequent urination, uncontrollable urination and urgency urinary incontinence. The drug may help improve the quality of life of patients suffering from these symptoms and reduce their frequency and urgency of urination.

The dosage and regimen of Vesigamp may vary depending on the individual needs of the patient and the doctor’s recommendations. The drug is usually taken in tablet form once a day, but the dosage may be adjusted by your doctor depending on the effectiveness and tolerability of the drug.

Indications Vesigampa

1. Burning Frequency Syndrome (OAB): This is a condition in which the patient experiences frequent and/or uncontrollable urination due to an overactive bladder. Vesigamp may help reduce the frequency and urgency of urination.
2. Urgency urinary incontinence: Patients with this condition experience a sudden and irresistible urge to urinate, which can lead to urinary incontinence. Vesigamp may help reduce urinary urgency and improve urinary control.
3. Urinary incontinence: This is a condition in which the patient experiences inability to control urination, which can lead to accidents. Vesigamp may help improve urinary control and reduce urinary incontinence.

Release form

Vesigamp can be produced in the form of tablets or capsules for oral (internal) use.

Pharmacodynamics

1. Mechanism of action: Solifenacin is an antagonist of muscarinic receptors, primarily M3 receptors, which are located in the smooth muscles of the bladder. By blocking these receptors, solifenacin reduces the activity of the muscarinic nervous system, which results in decreased spontaneous activity of the bladder and an increase in bladder capacity.
2. Reduction in bladder spasms: Blocking muscarinic receptors in the smooth muscle of the bladder results in decreased spasms and a decrease in the frequency of bladder contractions, which relieves symptoms of urinary incontinence.
3. Increase in bladder capacity: Blocking muscarinic receptors also results in the relaxation of the bladder wall, which allows it to hold more urine before the need to urinate.
4. Improvement in urinary incontinence symptoms: Through its mechanism of action, solifenacin helps improve symptoms of urinary incontinence such as urinary frequency, inability to control urination, and the frequent urge to urinate. Urination.

Pharmacokinetics

1. Absorption: After oral administration, solifenacin is well absorbed from the gastrointestinal tract. Peak plasma concentrations are usually reached 3-8 hours after administration.
2. Metabolism: Solifenacin is metabolized in the liver to form the active metabolite (N-demethylated solifenacin), which is the major metabolite and has pharmacological activity similar to the parent compound. This metabolite is formed by the enzyme CYP3A4.
3. Elimination: Solifenacin and its metabolite are excreted primarily in the urine and to a lesser extent in the feces.
4. Half-life: Solifenacin has a half-life of approximately 45-68 hours, allowing it to be taken once daily to maintain steady-state blood concentrations.
5. Dose linearity: Solifenacin pharmacokinetics are generally linear over the dose range of 5 to 40 mg.
6. Factors affecting pharmacokinetics: Certain factors, such as age, gender, and liver or kidney impairment, may affect the pharmacokinetics of solifenacin, which may require dose adjustments in some patients. Patients.

Dosing and administration

1. Tablets or capsules are taken orally whole, with a small amount of water.
2. The dosage usually starts low or medium and can be gradually adjusted depending on the effectiveness and tolerability of the drug.
3. The usual recommended starting dose for adults is 5 mg once daily. In some cases, the dose can be increased to 10 mg once a day, but only on the recommendation of a doctor.
4. The drug is usually taken at the same time every day, preferably in the morning.
5. Dosage for children and adolescents should be determined by a physician based on their age, weight, and medical history.

Use Vesigampa during pregnancy

The use of solifenacin (Vesigam) during pregnancy is not recommended due to insufficient data on its safety for the fetus. The following are conclusions from available research:

1. A study of the pharmacokinetic interaction of solifenacin with oral contraceptives showed that solifenacin does not affect the pharmacokinetics of ethinyl estradiol and levonorgestrel, which may be relevant when used during reproductive age. However, this study did not examine the safety of solifenacin during pregnancy itself (Taekema-Roelvink et al., 2005).
2. A study of the efficacy and safety of post-micturition dribbling in women did not reveal significant differences between solifenacin and placebo. The study did not include a specific group of pregnant women, so the data on the safety of solifenacin during pregnancy remain limited (Ablove et al., 2018).

Due to insufficient data on the safety of solifenacin during pregnancy, it is important to consult a doctor before using it to assess all potential risks to fetal development.

Contraindications

1. Hypersensitivity: People with a known hypersensitivity or allergic reaction to solifenacin or other components of the drug should avoid using it.
2. Glaucoma: The drug may increase intraocular pressure, so its use is not recommended for open-angle glaucoma or in patients at risk of developing it.
3. Urethral obstruction: Solifenacin may cause urinary retention and may not be used in patients with urethral obstruction.
4. Tachyarrhythmias: The use of solifenacin may be contraindicated in patients with tachyarrhythmias as it may increase heart rate.
5. Severe gastrointestinal disorders: In cases of acute constipation, ulcerative colitis, obstructive bowel disorders or other serious gastrointestinal disorders, the use of solifenacin may be undesirable.
6. Bronchial asthma: The drug should be used with caution in patients with bronchial asthma due to its antagonistic effect on muscarinic receptors.
7. Severe liver and kidney impairment: If you have severe liver or kidney impairment, consult your doctor before starting solifenacin.

Side effects Vesigampa

1. Dry mouth: This is one of the most common side effects of solifenacin. Patients may experience a feeling of dry mouth, which can lead to discomfort and a need for mouth moisture.
2. Constipation: In some patients, solifenacin may cause difficulty with bowel movements and constipation due to its antispasmodic effect on smooth muscle.
3. Increased heart rate: Some patients may experience increased heart rate or palpitations while taking solifenacin.
4. Stomach upset: Stomach upset such as nausea, vomiting or indigestion may occur.
5. Headache: Some patients may experience headaches while taking solifenacin.
6. Urinary disorders: Side effects related to urination, such as decreased urine flow or painful urination, may occur.
7. Fatigue: Solifenacin may cause fatigue or drowsiness in some patients.
8. Rare side effects: These may include allergic reactions, visual disturbances, hypersensitivity to sunlight and other rare side effects.

Overdose

An overdose of Vesigamp can cause serious side effects and complications. Signs of overdose may include increased symptoms of side effects such as dry mouth, constipation, visual disturbances, tachycardia, arrhythmias, drowsiness, dizziness and others.

Interactions with other drugs

1. Drugs that cause QT prolongation: Use of solifenacin with drugs that may cause QT prolongation, such as antiarrhythmic drugs (eg, amidarone, sotalol) or some antidepressants (eg, citalopram, fluoxetine), may increase the risk of cardiac arrhythmias.
2. Antifungal drugs: Some antifungal drugs, such as ketoconazole and itraconazole, may increase the blood levels of solifenacin, which may increase its side effects.
3. Drugs that have anticholinergic properties: Use of solifenacin with other drugs that have anticholinergic properties (for example, antihistamines, antispasmodics) may increase its undesirable effects, such as dry mouth or constipation.
4. Drugs metabolized by the CYP3A4 enzyme: Solifenacin is metabolized by the CYP3A4 enzyme in the liver, so the use of solifenacin with drugs that inhibit or induce this enzyme (for example, proton pump inhibitors, antibiotics, antiepileptic drugs) may alter its blood levels.